Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tenofovir amibufenamide (HS-10234) (HS-10234) 是一种 Tenofovir 前药,是一种具有口服活性的抗病毒化合物。Tenofovir amibufenamide 对乙型肝炎病毒 (HBV)具有抑制作用,可用于慢性乙型肝炎 (CHB) 研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,930 | 现货 | ||
5 mg | ¥ 6,890 | 现货 | ||
10 mg | ¥ 9,350 | 现货 | ||
25 mg | ¥ 13,800 | 现货 | ||
50 mg | ¥ 18,700 | 现货 | ||
100 mg | ¥ 25,200 | 现货 |
产品描述 | Tenofovir amibufenamide (HS-10234) (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies. |
靶点活性 | Anti-HBV:7.29 ± 0.71 nM(EC50) |
体外活性 | TMF and TAF exhibited significantly stronger inhibition of HBV DNA replication than did TDF in HBV-positive HepG2.2.15 cells. The anti-HBV activity of TMF was slightly stronger than TAF after 9 days of treatment (EC50 7.29 ± 0.71 nM vs. 12.17 ± 0.56 nM). The callback effects of the three TFV ester prodrugs were ranked as TMF > TAF > TDF. These advantages of TMF were believed to be attributed to its greater bioavailability in preclinical animals (SD rats, C57BL/6 mice and beagle dogs) and better target loading, especially in terms of the higher hepatic level of the pharmacologically active metabolite TFV-DP, which was tightly related to anti-HBV efficacy. [1] |
体内活性 | Safety was evaluated thoroughly focusing on bone, renal, and metabolic parameters between TMF (25 mg, for 96 weeks) and TDF group. Non-indexed estimated glomerular filtration rate for renal safety assessment was adopted, while a smaller decline of which was seen in the TMF group than in the TDF group (p=0.01). For bone mineral density, patients receiving TMF displayed significantly lower reduction levels in the densities of spine, hip, and femur neck at week 96 than those receiving TDF. In addition, the lipid parameters were stable after week 48 in all groups while weight change still showed the opposite trend. TMF maintained similar efficacy at week 96 compared with TDF with continued superior bone and renal safety profiles.[2] |
别名 | HS-10234 |
分子量 | 490.49 |
分子式 | C22H31N6O5P |
CAS No. | 1571076-26-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 180.0 mg/mL (367.0 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0388 mL | 10.1939 mL | 20.3878 mL | 50.9694 mL |
5 mM | 0.4078 mL | 2.0388 mL | 4.0776 mL | 10.1939 mL | |
10 mM | 0.2039 mL | 1.0194 mL | 2.0388 mL | 5.0969 mL | |
20 mM | 0.1019 mL | 0.5097 mL | 1.0194 mL | 2.5485 mL | |
50 mM | 0.0408 mL | 0.2039 mL | 0.4078 mL | 1.0194 mL | |
100 mM | 0.0204 mL | 0.1019 mL | 0.2039 mL | 0.5097 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tenofovir amibufenamide 1571076-26-0 Microbiology/Virology HBV HS10234 HS-10234 HS 10234 Inhibitor inhibitor inhibit